DK1589031T3 - Fremstillingaf polyketider og andre naturlige produkter - Google Patents
Fremstillingaf polyketider og andre naturlige produkterInfo
- Publication number
- DK1589031T3 DK1589031T3 DK05075774T DK05075774T DK1589031T3 DK 1589031 T3 DK1589031 T3 DK 1589031T3 DK 05075774 T DK05075774 T DK 05075774T DK 05075774 T DK05075774 T DK 05075774T DK 1589031 T3 DK1589031 T3 DK 1589031T3
- Authority
- DK
- Denmark
- Prior art keywords
- compounds
- fkbp
- polyketides
- natural products
- analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/76—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Actinomyces; for Streptomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polyesters Or Polycarbonates (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0216509A GB0216509D0 (en) | 2002-07-16 | 2002-07-16 | Production of polyketides and other natural products |
GB0224922A GB0224922D0 (en) | 2002-10-25 | 2002-10-25 | Production of polyketides and other natural products |
PCT/GB2003/003230 WO2004007709A2 (en) | 2002-07-16 | 2003-07-16 | Production of polyketides |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1589031T3 true DK1589031T3 (da) | 2007-12-10 |
Family
ID=30117119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05075774T DK1589031T3 (da) | 2002-07-16 | 2003-07-16 | Fremstillingaf polyketider og andre naturlige produkter |
Country Status (16)
Country | Link |
---|---|
US (7) | US7300942B2 (es) |
EP (5) | EP1967520A2 (es) |
JP (5) | JP2005532809A (es) |
CN (1) | CN100569944C (es) |
AT (1) | ATE370161T1 (es) |
AU (1) | AU2003246965B2 (es) |
BR (1) | BR0312691A (es) |
CA (1) | CA2492153C (es) |
CY (1) | CY1107764T1 (es) |
DE (1) | DE60315723T2 (es) |
DK (1) | DK1589031T3 (es) |
ES (2) | ES2544624T3 (es) |
HK (1) | HK1077845A1 (es) |
MX (1) | MXPA05000139A (es) |
PT (1) | PT1589031E (es) |
WO (1) | WO2004007709A2 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1967520A2 (en) * | 2002-07-16 | 2008-09-10 | Biotica Technology Limited | Production of polyketides and other natural products |
JP2007534337A (ja) * | 2004-04-27 | 2007-11-29 | ワイス | ラパマイシン特異的メチラーゼを用いるラパマイシンの標識 |
AU2005252673A1 (en) | 2004-06-03 | 2005-12-22 | Wyeth | Biosynthetic gene cluster for the production of a complex polyketide |
GB0417852D0 (en) | 2004-08-11 | 2004-09-15 | Biotica Tech Ltd | Production of polyketides and other natural products |
JP2008524232A (ja) | 2004-12-20 | 2008-07-10 | ワイス | ラパマイシン誘導体及び神経障害の治療におけるその使用 |
US7276498B2 (en) | 2004-12-20 | 2007-10-02 | Wyeth | Rapamycin analogues and uses thereof in the treatment of neurological disorders |
DK1848431T3 (en) | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
BRPI0608726A2 (pt) * | 2005-03-11 | 2011-03-15 | Biotica Tech Ltd | uso de um análogo de 39-desmetoxirapamicina ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica |
GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
CA2599547A1 (en) * | 2005-03-11 | 2006-09-14 | Biotica Technology Limited | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
GB0504995D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Use of a compound |
JP5528708B2 (ja) | 2006-02-09 | 2014-06-25 | 参天製薬株式会社 | 安定な製剤ならびにそれらを調製および使用する方法 |
CN103127100A (zh) | 2006-03-23 | 2013-06-05 | 参天制药株式会社 | 用于与血管通透性有关的疾病或病症的制剂和方法 |
GB0609962D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
GB0609963D0 (en) | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
KR100750810B1 (ko) | 2006-08-07 | 2007-08-22 | 동국제약 주식회사 | 스트렙토마이세스 히그로스코피쿠스 atcc 14891변이주 및 이를 이용한 타크로리무스 생산 방법 |
WO2008119134A1 (en) * | 2007-04-02 | 2008-10-09 | Newsouth Innovations Pty Limited | Methods for producing secondary metabolites |
TW200845960A (en) * | 2007-04-05 | 2008-12-01 | Wyeth Corp | Wortmannin-rapalog conjugate and uses thereof |
US20080287675A1 (en) * | 2007-05-18 | 2008-11-20 | Abbott Laboratories | Cascade system |
WO2009089549A1 (en) * | 2008-01-11 | 2009-07-16 | Massachusetts Eye & Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
CN102224242B (zh) | 2008-09-24 | 2014-09-24 | 中国科学院上海有机化学研究所 | 新基因簇 |
GB0904540D0 (en) | 2009-03-17 | 2009-04-29 | Biotica Tech Ltd | Novel compounds and methods for their production |
GB0914589D0 (en) | 2009-08-20 | 2009-09-30 | Biotica Tech Ltd | Novel compounds and methods for their production |
GB0917817D0 (en) | 2009-10-12 | 2009-11-25 | Biotica Tech Ltd | Novel compounds and methods for their production |
GB0917816D0 (en) | 2009-10-12 | 2009-11-25 | Biotica Tech Ltd | Novel compounds and methods for their production |
US9096587B2 (en) | 2010-12-08 | 2015-08-04 | Oslo University Hospital Hf | Triazole derivatives as Wnt signaling pathway inhibitors |
EP2589383A1 (en) | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
GB201122305D0 (en) | 2011-12-23 | 2012-02-01 | Biotica Tech Ltd | Novel compound |
CN103212064B (zh) * | 2012-01-19 | 2016-02-17 | 中国科学院上海巴斯德研究所 | 磷酸化途径相关因子在调控调节性t细胞功能中的应用 |
KR101331491B1 (ko) | 2012-03-21 | 2013-11-20 | 이화여자대학교 산학협력단 | 증가된 라파마이신 생성능을 갖는 신규 미생물 균주 |
GB201312318D0 (en) | 2013-07-09 | 2013-08-21 | Isomerase Therapeutics Ltd | Novel methods and compounds |
WO2017040341A1 (en) * | 2015-08-28 | 2017-03-09 | Buck Institute For Research On Aging | RAPAMYCIN ANALOGS SHOWING IMPROVED mTORC1 SPECIFICITY |
SG11201908226XA (en) | 2017-02-10 | 2019-10-30 | Mount Tam Therapeutics Inc | Rapamycin analog |
US20210030726A1 (en) * | 2018-02-09 | 2021-02-04 | Torcept Therapeutics, Inc. | Rapamycin analog for prevention and/or treatment of neurodegnerative conditions |
WO2019157363A2 (en) * | 2018-02-09 | 2019-08-15 | Mount Tam Therapeutics, Inc. | Rapamycin analog for prevention and/or treatment of cancer |
GB2586764B (en) | 2019-01-22 | 2022-02-09 | Aeovian Pharmaceuticals Inc | MTORC modulators and uses thereof |
CN115125179B (zh) * | 2021-03-26 | 2023-10-27 | 上海医药工业研究院 | 产雷帕霉素的基因工程菌及其应用 |
EP4359417A2 (en) * | 2021-06-25 | 2024-05-01 | Apertor Pharmaceuticals, Inc. | Small molecule compounds |
WO2022272129A1 (en) * | 2021-06-25 | 2022-12-29 | Edmund Graziani | Small molecule compounds |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
SE416705B (sv) | 1978-02-27 | 1981-02-02 | Torsten & Andersson Kaj | Anordning for utskjutning av bollar |
GB2165090A (en) | 1984-09-26 | 1986-04-03 | Philips Electronic Associated | Improving the field distribution in high voltage semiconductor devices |
JPS6453991A (en) | 1987-08-25 | 1989-03-01 | Mitsubishi Electric Corp | Magazine-cum-reel |
US5109112A (en) | 1989-01-19 | 1992-04-28 | Merck & Co., Inc. | FK-506 cytosolic binding protein |
US5023262A (en) | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
US5221670A (en) | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
US5143918A (en) * | 1990-10-11 | 1992-09-01 | Merck & Co., Inc. | Halomacrolides and derivatives having immunosuppressive activity |
WO1993013663A1 (en) | 1992-01-17 | 1993-07-22 | Abbott Laboratories | Method of directing biosynthesis of specific polyketides |
US5093338A (en) * | 1991-04-23 | 1992-03-03 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
US5091389A (en) * | 1991-04-23 | 1992-02-25 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
US5138051A (en) | 1991-08-07 | 1992-08-11 | American Home Products Corporation | Rapamycin analogs as immunosuppressants and antifungals |
WO1992021341A1 (en) | 1991-05-31 | 1992-12-10 | Pfizer Inc. | Use of rapamycin prodrugs as immunosuppressant agents |
US5763590A (en) | 1991-10-11 | 1998-06-09 | Vertex Pharmaceuticals, Inc. | Isolation of an Mr 52,000 FK506 binding protein and molecular cloning of a corresponding human cDNA |
GB9125660D0 (en) * | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
US5498597A (en) | 1992-01-17 | 1996-03-12 | Dana-Farber Cancer Institute, Inc. | FKBP-13, an FK506-binding immunophilin |
JP3140228B2 (ja) | 1992-02-17 | 2001-03-05 | ファイザー製薬株式会社 | 新規な大環状ラクトンおよびその生産菌 |
ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
GB9302569D0 (en) | 1993-02-10 | 1993-03-24 | Smithkline Beecham Plc | Novel compound |
US5354845A (en) | 1993-04-21 | 1994-10-11 | Children's Research Institute | FK-506 and rapamycin specific binding immunophilin |
GB9315914D0 (en) | 1993-07-31 | 1993-09-15 | Smithkline Beecham Plc | Novel compound |
US5391730A (en) | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
US5378836A (en) | 1993-10-08 | 1995-01-03 | American Home Products Corporation | Rapamycin oximes and hydrazones |
US5373014A (en) | 1993-10-08 | 1994-12-13 | American Home Products Corporation | Rapamycin oximes |
UA41884C2 (uk) * | 1993-11-05 | 2001-10-15 | Амерікан Хоум Продактс Корпорейшн | Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів |
WO1995014023A1 (en) * | 1993-11-19 | 1995-05-26 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
SK78196A3 (en) | 1993-12-17 | 1997-02-05 | Sandoz Ag | Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them |
US5457182A (en) | 1994-02-15 | 1995-10-10 | Merck & Co., Inc. | FK-506 cytosolic binding protein, FKBP12.6 |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US5563145A (en) | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
CA2219659C (en) | 1995-06-09 | 2008-03-18 | Novartis Ag | Rapamycin derivatives |
ATE286133T1 (de) | 1995-07-06 | 2005-01-15 | Univ Leland Stanford Junior | Zellfreie synthese von polyketiden |
US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
GB9710962D0 (en) | 1997-05-28 | 1997-07-23 | Univ Cambridge Tech | Polyketides and their synthesis |
ATE451455T1 (de) | 1996-07-05 | 2009-12-15 | Biotica Tech Ltd | Hybridpolyketidesynthase i gen |
CA2261666C (en) | 1996-07-30 | 2010-09-14 | Novartis Ag | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin |
AU4246197A (en) * | 1996-09-09 | 1998-03-26 | American Home Products Corporation | Rapamycin derivatives with unnatural stereochemistries |
CA2286311A1 (en) * | 1997-04-09 | 1998-10-15 | Isotechnika, Inc. | Method for production of antibodies to specific sites of rapamycin |
US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
WO1999064040A1 (en) * | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Novel polyene macrolide compounds and uses |
GB9814006D0 (en) | 1998-06-29 | 1998-08-26 | Biotica Tech Ltd | Polyketides and their synthesis |
GB9814622D0 (en) | 1998-07-06 | 1998-09-02 | Biotica Tech Ltd | Polyketides,their preparation,and materials for use therein |
US6150513A (en) | 1998-09-16 | 2000-11-21 | Kosan Biosciences, Inc. | Polyketide synthase enzymes and recombinant DNA constructs therefor |
NZ510819A (en) * | 1998-10-02 | 2004-03-26 | Kosan Biosciences Inc | Polyketide synthase enzymes and recombinant DNA constructs therefor |
SE516023C2 (sv) | 1999-06-24 | 2001-11-12 | Abb Ab | Industrirobot innefattande en växellådskonfiguration samt förfarande i en industrirobot |
CA2377918A1 (en) | 1999-07-09 | 2001-01-18 | Bruce G. Gold | Compositions and methods for promoting nerve regeneration |
US6569867B2 (en) * | 1999-10-01 | 2003-05-27 | Kosan Biosciences, Inc. | Polyketide derivatives |
AU2748701A (en) | 1999-10-29 | 2001-06-06 | Kosan Biosciences, Inc. | Rapamycin analogs |
DK1278881T3 (da) | 2000-04-13 | 2010-05-10 | Biotica Tech Ltd | Glycosylerede hybrid-produkter og deres fremstilling og anvendelse |
EP1282626A2 (en) * | 2000-05-17 | 2003-02-12 | Kosan Biosciences, Inc. | Polyketide derivatives |
GB0019986D0 (en) | 2000-08-14 | 2000-10-04 | Biotica Tech Ltd | Polyketides and their synthesis |
US6534693B2 (en) * | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
GB0128680D0 (en) | 2001-11-29 | 2002-01-23 | Biotica Tech Ltd | Hybrid glycosylated products and their production and use |
CN100522967C (zh) * | 2002-02-01 | 2009-08-05 | 阿里亚德基因治疗公司 | 含磷化合物及其应用 |
AU2007237187B2 (en) | 2002-07-16 | 2010-08-05 | Biotica Technology Limited | Production of polyketides |
CA2621517C (en) | 2002-07-16 | 2014-03-25 | Biotica Technology Limited | Production of polyketides fkbp-ligand analogues |
EP1967520A2 (en) | 2002-07-16 | 2008-09-10 | Biotica Technology Limited | Production of polyketides and other natural products |
GB0216509D0 (en) | 2002-07-16 | 2002-08-28 | Biotica Tech Ltd | Production of polyketides and other natural products |
-
2003
- 2003-07-16 EP EP08075113A patent/EP1967520A2/en not_active Withdrawn
- 2003-07-16 PT PT05075774T patent/PT1589031E/pt unknown
- 2003-07-16 ES ES03764029.9T patent/ES2544624T3/es not_active Expired - Lifetime
- 2003-07-16 US US10/497,135 patent/US7300942B2/en not_active Expired - Lifetime
- 2003-07-16 JP JP2004520912A patent/JP2005532809A/ja active Pending
- 2003-07-16 EP EP05077470A patent/EP1655372A3/en not_active Withdrawn
- 2003-07-16 AT AT05075774T patent/ATE370161T1/de active
- 2003-07-16 EP EP05075774A patent/EP1589031B1/en not_active Expired - Lifetime
- 2003-07-16 CN CNB038169169A patent/CN100569944C/zh not_active Expired - Fee Related
- 2003-07-16 BR BR0312691-9A patent/BR0312691A/pt not_active IP Right Cessation
- 2003-07-16 WO PCT/GB2003/003230 patent/WO2004007709A2/en active Application Filing
- 2003-07-16 EP EP03764029.9A patent/EP1521828B1/en not_active Expired - Lifetime
- 2003-07-16 DE DE60315723T patent/DE60315723T2/de not_active Expired - Lifetime
- 2003-07-16 CA CA2492153A patent/CA2492153C/en not_active Expired - Fee Related
- 2003-07-16 AU AU2003246965A patent/AU2003246965B2/en not_active Ceased
- 2003-07-16 DK DK05075774T patent/DK1589031T3/da active
- 2003-07-16 ES ES05075774T patent/ES2296063T3/es not_active Expired - Lifetime
- 2003-07-16 EP EP10179385A patent/EP2277898A3/en not_active Withdrawn
- 2003-07-16 MX MXPA05000139A patent/MXPA05000139A/es active IP Right Grant
-
2005
- 2005-11-07 HK HK05109892.5A patent/HK1077845A1/xx not_active IP Right Cessation
- 2005-11-08 US US11/269,215 patent/US20060078980A1/en not_active Abandoned
-
2007
- 2007-07-16 US US11/778,264 patent/US7390895B2/en not_active Expired - Lifetime
- 2007-07-16 US US11/778,319 patent/US7645768B2/en not_active Expired - Fee Related
- 2007-10-15 CY CY20071101328T patent/CY1107764T1/el unknown
- 2007-10-31 US US11/931,474 patent/US20080287482A1/en not_active Abandoned
-
2008
- 2008-02-07 JP JP2008028178A patent/JP2008200039A/ja not_active Ceased
- 2008-02-07 JP JP2008028177A patent/JP4751899B2/ja not_active Expired - Fee Related
-
2009
- 2009-11-09 JP JP2009255660A patent/JP2010075187A/ja not_active Withdrawn
-
2011
- 2011-03-11 US US13/046,304 patent/US9040259B2/en not_active Expired - Lifetime
-
2014
- 2014-04-09 JP JP2014080591A patent/JP2014176384A/ja active Pending
-
2015
- 2015-03-02 US US14/635,979 patent/US9605001B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1589031T3 (da) | Fremstillingaf polyketider og andre naturlige produkter | |
Widjaja et al. | Elongation factor Tu is a multifunctional and processed moonlighting protein | |
Davis et al. | Directing evolution: the next revolution in drug discovery? | |
Shin et al. | An E. coli cell-free expression toolbox: application to synthetic gene circuits and artificial cells | |
Yang et al. | Generation of an artificial double promoter for protein expression in Bacillus subtilis through a promoter trap system | |
Fischetti | Surface proteins on Gram-positive bacteria | |
NO20075088L (no) | Vertscelle omfattende en vektor for fremstilling av proteiner som krever gamma-karboksylering | |
Choi et al. | Enhanced production of recombinant proteins with Corynebacterium glutamicum by deletion of insertion sequences (IS elements) | |
WO2007005837A3 (en) | Inducible expression vectors and methods of use thereof | |
EP1576160B8 (en) | Borrelidin-derivatives and their use in medicine | |
NO20070757L (no) | Ny sekvens for forbedring av ekspresjon av nukleinsyre(r) | |
JPWO2021100640A5 (es) | ||
WO2005093069A3 (en) | Production of mersacidin and its variants in sigh and/or mrsa negative bacillus host cells | |
Kwon et al. | Non‐natural amino acids for protein engineering and new protein chemistries | |
Pek et al. | Exploring codon context bias for synthetic gene design of a thermostable invertase in Escherichia coli | |
ATE532861T1 (de) | Expressionsvektor | |
NO20025146L (no) | Isolering og karakterisering av csa-operonet (ETEC-CS4 pili) og fremgangsmåter for anvendelse derav | |
Sun et al. | Development of a N-acetylneuraminic acid-based sensing and responding switch for orthogonal gene regulation in cyanobacterial Synechococcus strains | |
Zhang et al. | Construction of an expression vector that uses the aph promoter for protein expression in Corynebacterium glutamicum | |
Li et al. | Engineering of Bacillus promoters based on interacting motifs between UP elements and RNA polymerase (RNAP) α-subunit | |
EP1321517A3 (en) | Gluconobacter oxydans 2-ketoreductase enzyme and applications thereof | |
WO2020247803A2 (en) | Frameshift suppressor trna compositions and methods of use | |
ATE495245T1 (de) | Verbesserte proteinexpression in bacillus subtilis | |
Thompson et al. | Characterization of an ECF56-family sigma factor from Streptomyces venezuelae reveals a highly conserved regulome | |
Fages-Lartaud et al. | Standard Intein Gene Expression Ramps (SIGER) for protein-independent expression control |